These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 19947816)

  • 21. Insulin and GLP-1 analog combinations in type 2 diabetes mellitus: a critical review.
    Jendle J; Martin SA; Milicevic Z
    Expert Opin Investig Drugs; 2012 Oct; 21(10):1463-74. PubMed ID: 22799463
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An overview of the pharmacokinetics, efficacy and safety of liraglutide.
    Bode B
    Diabetes Res Clin Pract; 2012 Jul; 97(1):27-42. PubMed ID: 22245694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sitagliptin: a novel drug for the treatment of type 2 diabetes.
    Choy M; Lam S
    Cardiol Rev; 2007; 15(5):264-71. PubMed ID: 17700385
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Drug therapy of type 2 diabetes and cardiovascular prevention: potentials for liraglutide].
    Reboldi G
    G Ital Cardiol (Rome); 2009 Jul; 10(7):434-47. PubMed ID: 19761101
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus.
    Neumiller JJ; Campbell RK
    Ann Pharmacother; 2009 Sep; 43(9):1433-44. PubMed ID: 19638470
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in Germany.
    Miller LA; Burudpakdee C; Zagar A; Bhosle M; Reaney M; Schabert VF; Bruhn D
    J Med Econ; 2012; 15(4):746-57. PubMed ID: 22443463
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liraglutide (Victoza) for type 2 diabetes.
    Med Lett Drugs Ther; 2010 Apr; 52(1335):25-7. PubMed ID: 20360660
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liraglutide: a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes mellitus.
    Joffe D
    Am J Health Syst Pharm; 2010 Aug; 67(16):1326-36. PubMed ID: 20689121
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus.
    Vilsbøll T
    Expert Opin Investig Drugs; 2007 Feb; 16(2):231-7. PubMed ID: 17243943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First fixed-ratio combination of insulin degludec and liraglutide for the treatment of type 2 diabetes.
    Rendell M
    Drugs Today (Barc); 2015 Mar; 51(3):185-96. PubMed ID: 25876562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liraglutide: a new treatment for type 2 diabetes.
    Vilsboll T
    Drugs Today (Barc); 2009 Feb; 45(2):101-13. PubMed ID: 19343230
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liraglutide: a review of its use in type 2 diabetes mellitus.
    Croom KF; McCormack PL
    Drugs; 2009 Oct; 69(14):1985-2004. PubMed ID: 19747013
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials.
    Buse JB; Garber A; Rosenstock J; Schmidt WE; Brett JH; Videbæk N; Holst J; Nauck M
    J Clin Endocrinol Metab; 2011 Jun; 96(6):1695-702. PubMed ID: 21450987
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liraglutide: clinical pharmacology and considerations for therapy.
    Sisson EM
    Pharmacotherapy; 2011 Sep; 31(9):896-911. PubMed ID: 21923591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue.
    Russell-Jones D
    Mol Cell Endocrinol; 2009 Jan; 297(1-2):137-40. PubMed ID: 19041364
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide.
    Vilsbøll T; Garber AJ
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():41-9. PubMed ID: 22405268
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liraglutide: a review of its use in adult patients with type 2 diabetes mellitus.
    Scott LJ
    Drugs; 2014 Dec; 74(18):2161-74. PubMed ID: 25367717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide.
    Faurschou A; Knop FK; Thyssen JP; Zachariae C; Skov L; Vilsbøll T
    Acta Diabetol; 2014 Feb; 51(1):147-50. PubMed ID: 22160246
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The future use of liraglutide: implications of the LEAD-2 study for treatment guidelines in type 2 diabetes.
    Gadsby R
    Prim Care Diabetes; 2010 Oct; 4(3):139-44. PubMed ID: 20418194
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and pharmacodynamics of liraglutide, a long-acting, potent glucagon-like peptide-1 analog.
    Meece J
    Pharmacotherapy; 2009 Dec; 29(12 Pt 2):33S-42S. PubMed ID: 19947815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.